US EditionTenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI™, the First and Only Combination Eye Drop Approved to Treat Presbyopia
YUVEZZI combines carbachol and brimonidine tartrate to improve near vision with low side effects, benefiting 128 million U.S. adults with presbyopia, per Tenpoint Therapeutics.
- In a Jan 28, 2026 press release from London & Seattle, Tenpoint Therapeutics Ltd. said the U.S. Food and Drug Administration approved YUVEZZI 2.75%/0.1%, the first and only dual-agent eye drop for adults with presbyopia.
- Presbyopia affects about 128 million people in the U.S. and 2 billion worldwide, typically starting around age 45 as the eye's lens stiffens, with reading glasses, contact lenses, or surgery often falling short.
- Phase 3 BRIO I and II provided the basis for approval, showing the fixed-dose combination outperformed individual actives and met near-vision endpoints with three-line BUNVA improvement over 8 hours.
- Tenpoint plans a U.S. launch later this year and raised $235 million, including an $85 million Series B and a $150 million secured loan, CEO Henric Bjarke said.
- YUVEZZI starts working in about 30 minutes and can last up to 10 hours; common side effects include headache, impaired vision, and temporary eye pain, so patients should use caution when driving.
13 Articles
13 Articles
FDA approves Yuvezzi eye drop for presbyopia
The FDA approved Yuvezzi, an eye drop for the treatment of presbyopia, with broad U.S. availability expected in the second quarter, according to a press release from Tenpoint Therapeutics. Yuvezzi (carbachol 2.75%/brimonidine tartrate 0.1% ophthalmic solution), formerly known as Brimochol PF, achieves effect after around 30 minutes and lasts for up to 10 hours, according to Tenpoint. It is the
FDA OKs More Eye Drops That Can Replace Reading Glasses
(MedPage Today) -- The FDA approved carbachol/brimonidine tartrate ophthalmic solution (Yuvezzi) for adults with presbyopia, making it the first approved dual-agent eye drop therapy for age-related vision decline. The eye drops contain two active...
Presbyopia Eye Drop From Startup Tenpoint Gets FDA Approval, Paving Way for $235M Financing
Tenpoint Therapeutics’ Yuvezzi brings a combination approach to presbyopia compared to single mechanisms of action offered by once-daily eye drops from Orasis Pharmaceuticals, Lenz Therapeutics, and AbbVie. Yuvezzi’s commercialization will be supported by up to $235 million in financing.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
